Esperion Announces Inducement Grants Under NASDAQ Listing Rule

Biopharmaceutical company grants restricted stock units to 11 new employees

Published on Feb. 11, 2026

Got story updates? Submit your updates here. ›

Esperion, a commercial-stage biopharmaceutical company, announced that on February 10, 2026, it granted 40,200 restricted stock units (RSUs) to 11 new employees under the company's 2017 Inducement Equity Incentive Plan. The RSUs will vest over a period of one year and subsequent quarters, subject to the employees' continued employment with Esperion.

Why it matters

The inducement grants are a common practice for publicly traded companies to attract and retain talent, especially in the competitive biopharmaceutical industry. Esperion's announcement demonstrates its continued growth and investment in building a strong team to support its commercial operations and pipeline development.

The details

The RSUs granted to the 11 new employees will vest as follows: 25% on the one-year anniversary of the recipient's vesting commencement date, and the remaining 75% in 12 equal quarterly installments thereafter. The grants are subject to the terms and conditions of Esperion's 2017 Inducement Equity Incentive Plan.

  • On February 10, 2026, Esperion granted the 40,200 RSUs to 11 new employees.

The players

Esperion

A commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies.

Got photos? Submit your photos here. ›

The takeaway

Esperion's inducement grants demonstrate its commitment to building a strong team to support its commercial operations and pipeline development, which is crucial for a growing biopharmaceutical company in a competitive industry.